Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2000

View Archived Issues

Stimulation of brain reward areas by nicotine causes addiction

KS Biomedix forms collaboration with Eukarion

Serono to develop protein expression technology with Modex Therapeutics

Alendronate markedly reduces fracture risk in women with osteoporosis

Dietary changes affect homocysteine levels and possibly the risk of heart disease

Potential human pheromone receptor gene identified

Tobramycin shows promise in clinical study of bronchiectasis

Gliatech-Guilford merger terminated

Bayer announces large cerivastatin trial in acute MI

Randomized trial of cardiac resynchronization shows positive results

BioTime seeks European approval of Hextend

Simulect shows good results in pediatric transplant recipients

BioTransplant reports positive phase I/II results for BTI-322 in liver transplant patients

Zometa approved in Canada for treatment of tumor-induced hypercalcemia

Lung imaging agent from Nycomed Amersham enters phase I trial

FXR ligands synthesized by Glaxo Wellcome

NexMed presents results of topical alprostadil treatment

NIDDK reports design of GPCR ligands

Donor intestine irradiation improves survival

BioTransplant breeds miniswine without human-tropic PERV

Aventis reports MMP-12 inhibitors for the treament of emphysema in smokers

New anti-HIV compounds disclosed in patent literature by HHS

Asthma research at Bayer targets inhibition of MMP

New series of factor Xa inhibitors reported by German lab

Fujisawa continues research into treatments for urinary incontinence

New developments in neurological research at AstraZeneca

Anxiolytic and antidepressant compounds with a dual mechanism of action

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...